Oramed swings to Q2 FY26 net income of $78.16 million; operating loss widens 11% to $2.77 million

• Oramed posted net income of USD 78.16 million, equal to USD 1.84 per diluted share, for the three months ended June 30, 2026.
• Revenue was unchanged at no revenue, while operating loss widened 11% to USD 2.77 million.
• Financial income climbed to USD 103.74 million on revaluation of investments in Alpha Tau; other income rose to USD 610,400.
• Cash and cash equivalents fell to USD 15.25 million as of June 30, 2026; management expects funding to cover planned activities for 12 months.
• Nano Dimension stake stood at 6,879,708 shares as of Aug. 10, 2026 following post-quarter sales; Oramed agreed to invest up to USD 1 million in MAR Oramed JV.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-087361), on August 10, 2026, and is solely responsible for the information contained therein.